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ABSTRACT: Prothrombinase activates prothrombin through initial cleavage at Arg320 followed by cleavage
at Arg271. This pathway is characterized by the generation of an enzymatically active, transient intermediate,
meizothrombin, that has increased chromogenic substrate activity but poor clotting activity. The heavy
chain of factor Va contains an acidic region at the COOH terminus (residues 680-709). We have shown
that a pentapeptide from this region (DYDYQ) inhibits prothrombin activation by prothrombinase by
inhibiting meizothrombin generation. To ascertain the function of these regions, we have created a mutant
recombinant factor V molecule that is missing the last 30 amino acids from the heavy chain (factor
V∆680-709) and a mutant molecule with the 695DYDY698 f AAAA substitutions (factor V4A). The clotting
activities of both recombinant mutant factor Va molecules were impaired compared to the clotting activity
of wild-type factor Va (factor VaWt). Using an assay employing puriﬁed reagents, we found that
prothrombinase assembled with factor Va∆680-709 displayed an ∼39% increase in kcat, while prothrombinase
assembled with factor Va4A exhibited an ∼20% increase in kcat for the activation of prothrombin as compared
to prothrombinase assembled with factor VaWt. Gel electrophoresis analyzing prothrombin activation by
prothrombinase assembled with the mutant molecules revealed a delay in prothrombin activation with
persistence of meizothrombin. Our data demonstrate that the COOH-terminal region of factor Va heavy
chain is indeed crucial for coordinated prothrombin activation by prothrombinase because it regulates
meizothrombin cleavage at Arg271 and suggest that this portion of factor Va is partially responsible for
the enhanced procoagulant function of prothrombinase.
Blood coagulation is initiated at the site of vascular injury
and results in the activation of prothrombin to R-thrombin
by the prothrombinase complex. Prothrombinase is composed
of the enzyme factor Xa bound to its cofactor, factor Va, on
a phospholipid surface in the presence of Ca2+ (1). Pro-
thrombin and R-thrombin have two distinct exosites (anion
binding exosite I, ABE-I,
1 and anion binding exosite II, ABE-
II) that are responsible for the functions of the molecules.
The role of (pro)exosite I of prothrombin within prothrom-
binase is dependent on the incorporation of factor Va into
the complex (2, 3). Two pathways for prothrombin activation
are possible: membrane-bound factor Xa alone activates
prothrombin following initial cleavage at Arg271 followed
by cleavage at Arg320, while the fully assembled prothrom-
binase complex activates prothrombin following the opposite
pathway, initial cleavage at Arg320 followed by cleavage at
Arg271 (4–8). Activation of prothrombin via this latter
pathway is characterized by the generation of an intermediate,
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signiﬁcant increase in the catalytic efﬁciency of factor Xa
with respect to R-thrombin formation (9).
Human factor V circulates in plasma as a 330000 molec-
ular weight, single-chain protein that consists of three
domains in the order A1-A2-B-A3-C1-C2. Proteolytic
cleavage of the cofactor by R-thrombin occurs sequentially
at Arg709, Arg1018, and Arg1545 to produce a heterodimer
consisting of a heavy chain (Mr ∼ 105000) and a light chain
(Mr ∼ 74000) associated via divalent metal ions (10–12)
(Figure 1). The heavy chain of the cofactor contains an acidic
amino acid region that has been shown to be important for
cofactor function (amino acids 680-709) (13). Earlier data
have suggested that factor Va interacts with meizothrombin
(14) and that this acidic region is implicated in the productive
interaction of factor Va with prothrombin (15–17). Various
proteases can cleave this acidic region to produce a cofactor
with a truncated heavy chain (18–21). Gerads et al. ﬁrst
showed that it is possible to selectively eliminate the acidic
region from factor Va heavy chain by an enzyme puriﬁed
from the venom of the snake Naja naja oxiana (18). Using
proteins of bovine origin, the authors demonstrated that while
elimination of the COOH-terminal region of factor Va results
in a molecule with severely impaired clotting activity,
incorporation of the truncated cofactor molecule into pro-
thrombinase resulted in an increased kcat for the activation
of prothrombin (18). The same authors also showed that
cleavage of the human factor Va heavy chain by the same
enzyme results in a cofactor with impaired clotting activity
(18). Subsequently, Bakker et al. using the same puriﬁed
enzyme identiﬁed the cleavage site of the enzyme at His682
in the human factor Va heavy chain [this amino acid is
conserved in the bovine cofactor (22, 23)] and demonstrated
that prothrombinase assembled with a human factor Va
molecule missing the Asp683-Arg709 portion has an increased
kcat for the activation of prothrombin as compared to the kcat
of prothrombinase assembled with the plasma cofactor (19).
Afterward, Camire et al. using cathepsin G (CG) and human
neutrophil elastase demonstrated that prothrombinase as-
sembled with factor Va molecules missing the COOH-
terminal domain of the heavy chain results in enzymes that
consistently express higher kcat values, suggesting that these
molecules are “more active” cofactors than puriﬁed plasma
factor Va activated with R-thrombin in an assay using
puriﬁed reagents (20). Surprisingly, and in line with the initial
ﬁndings of Gerads et al. (18), the same factor Va molecules
exhibited a signiﬁcant decrease in clotting activity (20). More
recently, using a puriﬁed enzyme from the snake venom of
Naja nigricollis nigricollis, we have also shown that a factor
Va molecule missing a portion of the COOH terminus of
the heavy chain has decreased clotting activity (21). Alto-
gether, these studies reveal that removal of the acidic COOH-
terminal portion of factor Va heavy chain results in a cofactor
molecule that is deﬁcient in its clotting activity. However,
prothrombinase assembled with these truncated cofactor
molecules produces signiﬁcantly higher kcat values for
prothrombin activation when assessed in assays using puriﬁed
reagents and a chromogenic substrate speciﬁc for R-thrombin.
A molecular explanation for these paradoxical observations
has not yet been provided.
Approximately 35 years ago, Heldebrant and Mann ﬁrst
demonstrated that incubation of fragment 2 with R-thrombin
results in a signiﬁcant increase in the esterolytic activity of
the enzyme toward Tos-L-Arg-OMe (TAME) as compared
to the activity of R-thrombin alone toward the same substrate
(24). This increase in the esterase activity of R-thrombin was
concomitant with a decrease in its clotting activity (24).
Subsequently, Franza et al. (25), Morita et al. (26), and
Kornalik and Blomba ¨ck (27) reported that meizothrombin
(and meizothrombin desfragment 1) generated by a compo-
nent puriﬁed from the venom of Echis carinatus has poor
clotting activity and high esterolytic activity toward TAME.
Franza et al. speciﬁcally demonstrated that the meizothrom-
bin species generated by E. carinatus has esterolytic activity
toward TAME ∼30% higher than that of R-thrombin (25).
Concomitantly, Myrmel et al. provided concrete evidence
demonstrating that addition of fragment 2 to R-thrombin
increases signiﬁcantly the catalytic efﬁciency of the enzyme
toward TAME, compared to the efﬁciency of R-thrombin
alone against the same substrate (28). All these ﬁndings were
later corroborated by two independent studies using either
TAME or S-2238 (29–31), and it was hypothesized that there
may be subtle but signiﬁcant differences between the active
sites of R-thrombin and meizothrombin (29). This conclusion
was strengthened by earlier ﬁndings demonstrating that while
DAPA, a speciﬁc noncovalent active site inhibitor of
R-thrombin, interacts with prethrombin 2 with an afﬁnity
that is ∼30 times lower than that for R-thrombin, the inhibitor
does not bind prothrombin and prethrombin 1 (32), and by
data obtained using electron spin resonance to probe the
active sites of meizothrombin and R-thrombin (33). Col-
lectively, the ﬁndings suggest an important effect of cleavage
at Arg271 on the progressive formation of the active site of
R-thrombin, resulting in signiﬁcant conformational differ-
ences between the active sites of R-thrombin and meizo-
thrombin. More recently, structural data obtained from the
only crystal structure of meizothrombin available in the
literature [bovine meizothrombin desfragment 1 (34)] have
established that the molecule is impaired in its clotting
activity because it has not yet exposed ABE-II (which is
covered by fragment 2). However, it is important to note
that comparison of the structural data of various R-thrombin
molecules provided in the literature with the crystal structure
of meizothrombin (34) does not allow for a deﬁnite conclu-
FIGURE 1: Mutants of human factor V. Factor V is activated
following three sequential cleavages by R-thrombin at Arg709,
Arg1018, and Arg1545. These cleavages release the active cofactor
composed of heavy and light chains associated in the presence of
divalent metal ions, and two activation fragments. The COOH
terminus of the heavy chain contains an acidic hirudin-like amino
acid region that is important for cofactor function. The mutations
(deletions and point mutations) within the heavy chain are indicated
together with the designation for the recombinant mutant factor V
molecules created and used throughout the manuscript.
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We have recently used overlapping peptides from region
680-709 of the factor Va molecule to show that an acidic
pentapeptide with the sequence DYDYQ inhibits prothrom-
bin activation by prothrombinase in a competitive manner
with respect to substrate (21, 35). We have further demon-
strated that DYDYQ inhibits prothrombinase activity by
inhibiting meizothrombin generation (36). Using data ob-
tained with recombinant proteins, Toso and Camire have
recently suggested that the COOH-terminal region of the
factor Va heavy chain has no detectable effect on prothrom-
binase function (37). This conclusion was surprising and
inconsistent with their ﬁndings since their data showed that
(1) prothrombinase assembled with recombinant factor Va
molecules missing a portion or the entire hirudin-like
carboxyl-terminal end of the heavy chain (amino acid
residues 678–709) had an increased kcat for the activation of
prothrombin (from 129 to 150%) compared to prothrombi-
nase assembled with the wild-type molecule in an assay using
puriﬁed reagents and a chromogenic substrate speciﬁc for
R-thrombin; (2) initial velocity measurements using the same
assay demonstrated a 20-25% increase in the rate of
R-thrombin formation by prothrombinase assembled with the
same recombinant mutant cofactor molecules that were
truncated at their carboxyl-terminal end; and (3) a recom-
binant factor Va molecule that is missing 17 amino acids
from the carboxy-terminal portion of the heavy chain had
decreased clotting activity (37). All these data are in complete
accord with all earlier ﬁndings using plasma-derived factor
Va molecules truncated at the carboxy-terminal end of their
heavy chain (18–21) and demonstrate a crucial but yet
undetermined contribution of the acidic COOH-terminal
region of the heavy chain of the cofactor to prothrombinase
activity during prothrombin activation.
It has been well established that while meizothrombin has
poor clotting activity, its amidolytic activity is increased
compared to that of R-thrombin toward small ﬂuorescent and
chromogenic substrates speciﬁcally used to assess R-throm-
bin activity (29–31, 38). A logical hypothesis for reconciling
all the ﬁndings described above is that the acidic COOH
terminus of factor Va heavy chain, and more precisely the
sequence DYDYQ, regulates meizothrombin concentration
during the factor Xa-catalyzed prothrombin activation by
prothrombinase. Thus, activation of prothrombin by pro-
thrombinase assembled with a cofactor that is missing the
acidic region will result in enhanced and stable meizothrom-
bin production. This result will be translated by a factor Va
molecule that is deﬁcient in its clotting activity but produces
an increase in kcat when introduced into prothrombinase. In
contrast, in the presence of an excess of the acidic region
[represented by DYDYQ (21, 35, 36)], no meizothrombin
is produced by prothrombinase, resulting in the generation
of R-thrombin through the alternative pathway characterized
by initial cleavage of prothrombin at Arg271 and transient
formation of prethrombin 2. This work was undertaken to
test these hypotheses and to elucidate the role of the acidic
COOH-terminal portion of the factor Va heavy chain during
activation of prothrombin by prothrombinase.
EXPERIMENTAL PROCEDURES
Materials, Reagents, and Proteins. Diisopropyl ﬂuoro-
phosphate (DFP), O-phenylenediamine dihydrochloride (OPD),
N-(2-hydroxyethyl)piperazine-N′-2-ethanesulfonic acid (Hepes),
Trizma (Tris base), and Coomassie Blue R-250 were
purchased from Sigma (St. Louis, MO). Factor V-deﬁcient
plasma was from Research Proteins Inc. (Essex Junction VT).
L-R-Phosphatidylserine (PS) and L-R-phosphatidylcholine
(PC) were from Avanti Polar Lipids (Alabaster, AL). Normal
reference plasma and the chromogenic substrate H-D-
hexahydrotyrosol-alanyl-arginyl-p-nitroanilide diacetate (Spec-
trozyme-TH) were purchased from American Diagnostica
Inc. (Greenwich, CT). H-D-Phenylalanyl-L-pipecolyl-L-argi-
nyl-p-nitroaniline dihydrochloride (Chromogenix, S-2238)
was purchased from Diapharma Group, Inc. (West Chester,
OH). RecombiPlasTin for the clotting assays was purchased
from Instrumentation Laboratory Co. (Lexington, MA). The
reversible ﬂuorescent R-thrombin inhibitor dansylarginine
N,N-(3-ethyl-1,5-pentanediyl)amide (DAPA), a polyclonal
antibody against factor V made in sheep, human prothrombin,
RVV-V activator, human R-thrombin, and active site-blocked
human meizothrombin [obtained following digestion of
prothrombin with the puriﬁed component from the venom
of the snake E. carinatus as described previously (30), FPR-
meizothrombin] were from Haematologic Technologies Inc.
(Essex Junction, VT). Human factor Xa was from Enzyme
Research Laboratories (South Bend, IN). Human cathepsin
G was from Calbiochem (EMD Chemicals, Inc., San Diego,
CA). All molecular biology and tissue culture reagents and
medium were from Gibco, Invitrogen Corp. (Grand Island,
NY). Human plasma factor V was puriﬁed and concentrated
using methodologies previously described employing the
monoclonal antibody RhFV#1 coupled to Sepharose (39).
Digestion of factor V by R-thrombin and cathepsin G (to
obtain factor VaIIa/CG)o rb yR-thrombin and the puriﬁed
enzyme from the venom of N. nigricollis nigricollis (factor
VaIIa/NN) were performed as described previously (20, 21).
The clotting activities of all factor Va preparations were
measured by a clotting assay using factor V-deﬁcient plasma
and standardized to the percentage of control as described
previously (39, 40) using an automated coagulation analyzer
(START-4, Diagnostica Stago, Parsippany, NJ). Recombinant
wild-type prothrombin and prothrombin rMZ-II that has only
one cleavage site for factor Xa (i.e., Arg320) were prepared
and puriﬁed as previously described (41). Phospholipid
vesicles composed of 75% PC and 25% PS (termed PCPS
vesicles throughout) were prepared as previously described
(42).
Construction of Recombinant FV Molecules. Mutant factor
V with the 695DYDY698 f AAAA substitutions (factor V4A)
was constructed using the QuickChange II XL site-directed
mutagenesis kit (Stratagene, La Jolla, CA) according to the
manufacturer’s instructions with the following primers
(underlined nucleotides represent the mismatch): 5′-GAT-
GAAGAGAGTGATGCTGCCGCTGCTGCCCA-
GAACAGA-3′ (sense) and 5′-TCTGTTCTGGGCAGCAGC-
GGCAGCATCACTCTCTTCATC-3′ (antisense). The deletion
mutant (factor V∆680-709) was constructed with the same kit.
Primers for factor V∆680-709 were 5′-CCTCCAGAATC-
TACAGTCATGGCTACACGGTCATTCCGAAACTCATC-
ATTGAATCAGG-3′ (sense) and 5′-CCTGATTCAATGA-
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TTCTGGAGG-3′ (antisense). PCR products were trans-
formed into competent Escherichia coli cells, and positive
ampicillin-resistant clones were selected. Before transfection,
all mutant constructs were veriﬁed following sequencing in
the Cleveland State University DNA Analysis Facility using
a Beckman Coulter CEQ 8000 Genetic Analysis System
(Beckman, Fullerton, CA) with factor V sequence-speciﬁc
primers. The wild-type pMT2-FV and mutant pMT2-FV
plasmids were isolated from the bacterial culture by the
QIAﬁlter High Speed plasmid Midi Kit (Qiagen Inc.,
Valencia, CA).
Expression of Recombinant Wild-Type and Mutant Factor
V in Mammalian Cells. COS-7L (Invitrogen) and COS-7 cells
(American type Tissue Collection, ATCC, Manassas, VA)
were maintained in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum and antibiotics
(100 µg/mL streptomycin and 100 IU/mL penicillin) in a
humidiﬁed atmosphere of 5% CO2 and 95% air at 37 °C.
Puriﬁed factor VWt, factor V∆680-709, and factor V4A plasmids
were transfected into the cells as described using FUGENE
6 (Roche Diagnostics, Basel, Switzerland) (43). Puriﬁcation
of all recombinant factor V molecules was performed as
described previously (44). The concentration of all molecules
was determined by an ELISA as detailed previously (43).
The activity and integrity of the recombinant molecules were
veriﬁed before and after activation with RVV-V activator
or R-thrombin by clotting assays using factor V-deﬁcient
plasma and by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) followed by Western blotting
using monoclonal and polyclonal antibodies. Full activation
of the cofactor molecules prior to use in various experiments
was ascertained by immunoblotting with both a mixture of
monoclonal antibodies to factor V heavy and light chains
(provided by K. G. Mann from the Department of Biochem-
istry, University of Vermont, Burlington, VT) and a poly-
clonal antibody to factor V made in sheep.
Analysis of Prothrombin ActiVation and FPR-Meizothrom-
bin CleaVage at Arg271 by Gel Electrophoresis. Prothrombin
(1.4 µM) was incubated with PCPS vesicles (20 µM), DAPA
(50 µM), and factor Va (10-30 nM) in a buffer composed
o f5m MC a 2+ in 20 mM Tris and 0.15 M NaCl (pH 7.4).
The reaction was initiated with the addition of factor Xa
(0.5-1 nM) at room temperature overa1htime course.
Aliquots (50 µL) from the reaction were removed at selected
time intervals (as indicated in the ﬁgure legends) treated as
described previously (36) and analyzed using 9.5% SDS-
PAGE. Prothrombin and prothrombin-derived fragments
were visualized by Coomassie Blue staining. Scanning
densitometry, calculation of the rates of prothrombin con-
sumption, and normalization to the prothrombin concentra-
tion were performed as described previously (36, 45, 46).
FPR-meizothrombin cleavage at Arg271 was assessed in a
similar manner using 12% SDS-PAGE.
Gel Electrophoresis and Western Blotting. SDS-PAGE
analyses of recombinant proteins following activation were
performed using 5 to 15% gradient gels according to the
method of Laemmli (47). Proteins were transferred to
polyvinylidene diﬂuoride (PVDF) membranes according to
the method described by Towbin et al. (48). After transfer
to PVDF membranes, factor Va heavy and light chain(s) were
detected using the appropriate monoclonal and polyclonal
antibodies (40). Immunoreactive fragments were visualized
with chemiluminescence.
Measurement of Rates of R-Thrombin Formation in a
Prothrombinase Assay. rMZ-II and recombinant prothrombin
were activated by prothrombinase prior to the experiment
using conditions previously described (49). Subsequent gel
electrophoresis analyses under reducing conditions were
performed to verify that both rMZ-II and the recombinant
prothrombin preparations were activated to the same extent
and that rMZ-IIa and recombinant R-thrombin formed had
comparable amounts of B chain. The enzymes (rMZ-IIa and
recombinant R-thrombin) used for the titration of Spetrozyme-
TH and S-2238 were assayed at a constant concentration (4.3
nM), as previously described using serial dilutions of
chromogenic substrate (45). The absorbance was monitored
with a Thermomax microplate reader (Molecular Devices,
Sunnyvale, CA). The data were plotted according to the
Michaelis-Menten equation using Prizm (Graphpad Soft-
ware Inc., San Diego, CA). A direct comparison between
active recombinant meizothrombin (rMZ-IIa) and recombi-
nant R-thrombin, for cleavage of spetrozyme-TH and S-2238,
demonstrated that the Vmax values of rMZ-IIa for Spec-
trozyme-TH and S-2238 are ∼2- and 1.5-fold higher,
respectively, than the Vmax of recombinant R-thrombin for
the same substrates. These data conﬁrm the ﬁndings in the
literature demonstrating the fact that meizothrombin has
higher catalytic efﬁciency than R-thrombin toward the
chromogenic peptidyl substrates generally used to assess for
R-thrombin activity (29–31, 38).
Functionally deﬁned apparent dissociation constants (KDapp)
for factor Va binding to factor Xa-PCPS were obtained from
plots measuring the rate of R-thrombin generation as a
function of factor Va concentration in the presence of a
limiting (constant) concentration of factor Xa. Throughout
all experiments, the assumption was n ) moles of factor Xa
bound per mole of factor Va at saturation; throughout this
study n ) 1. The stoichiometry of the factor Va-factor Xa
interaction was ﬁxed at 1. The initial rate of formation of
R-thrombin (initial velocity in nM IIa min-1) was calculated,
and the data were analyzed and plotted using Prizm according
to the one-binding site model. Dissociation constants were
extracted directly from the graphs.
The assay using puriﬁed reagents and verifying the activity
of the recombinant factor V molecules was conducted under
conditions where all factor Xa was saturated with factor Va,
as described by assessing R-thrombin formation by the
change in the absorbance of a chromogenic substrate at 405
nm (Spectrozyme-TH, 0.4 mM) (43, 45). All factor V
molecules were activated with RVV-V activator or R-throm-
bin as described previously (21, 35). Knowing the KDapp of
each factor Va species for factor Xa, we calculated the
amount necessary to saturate factor Xa using the quadratic
equation described in the literature (50) before each experi-
ment. The total concentration of ligand (VaT) used was
modiﬁed appropriately to yield 95-98% saturation of the
factor Xa molecule. The absorbance was monitored with a
Thermomax microplate reader and compared to that of a
R-thrombin standard prepared daily using puriﬁed plasma-
derived R-thrombin. The data were analyzed and plotted
using Prizm according to the Michaelis-Menten equation.
Kinetic constants provided throughout the paper were
extracted directly from the graphs.
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ActiVation of Recombinant Human Factor V Molecules.
To ascertain the function of the acidic region from the COOH
terminus of factor Va heavy chain for cofactor activity, we
constructed a molecule that is missing the entire amino acid
region 680-709 [factor V∆680-709 (Figure 1)]. We have also
constructed a factor V molecule with the 695DYDY698 f
AAAA mutations (factor V4A). The recombinant molecules
were expressed in mammalian cells and puriﬁed to homo-
geneity as described previously (44). Since factor V∆680-709
is missing Arg709 that is the activating cleavage site for
R-thrombin (Figure 1), in the functional assays, the recom-
binant mutant molecule was activated with RVV-V activator.
In contrast, factor V4A was activated with either RVV-V
activator or R-thrombin. SDS-PAGE analyses followed by
immunoblotting with speciﬁc monoclonal antibodies to the
heavy and light chain of the cofactor demonstrate that the
mutant recombinant proteins were intact, homogeneous, and
migrated according to their expected molecular weights
(Figure 2). In addition, control experiments using a poly-
clonal antibody to factor V demonstrate that all factor V
molecules were fully activated prior to use.
Cofactor Function of Recombinant Human Factor Va
Molecules. Recent work using recombinant factor Va mol-
ecules demonstrated that all cofactors lacking portions or
the entire acidic COOH terminus of the heavy chain
encompassing amino acid region 680-709 had KDapp values
for membrane-bound factor Xa that are similar to the values
for the bimolecular interaction found with the wild type or
the intact plasma cofactor (37). These values are similar to
the KDapp obtained with truncated plasma-derived factor Va
molecules for factor Xa (20, 21). Our studies with factor
Va∆680-709 also demonstrate that the mutant cofactor has an
afﬁnity for plasma-derived factor Xa similar to that of the
wild-type molecule (Figure 3A). Similar results were found
for factor Va4A (not shown). Thus, elimination of the acidic
COOH-terminal region of the factor Va heavy chain (amino
acid residues 680-709) is of no consequence with respect
to the afﬁnity of the cofactor for factor Xa.
Several studies have shown that plasma-derived or re-
combinant meizothrombin has increased activity (kcat) toward
chromogenic or ﬂuorescent substrates used to assess R-throm-
bin activity (8, 25, 31, 32, 38). This fact had been established
previously for DAPA (8, 32) and TAME (30). One early
study comparing the amidolytic activities between R-throm-
bin and meizothrombin using S-2238 demonstrated an ∼25%
increase in the kcat and an ∼18% increase in the second-
order rate constant of meizothrombin for S-2238 as compared
to the kcat and the second-order rate constant of R-thrombin
for the same substrate (31), and the general consensus is that
there are subtle but signiﬁcant differences between the active
sites of R-thrombin and meizothrombin (32, 33). We
evaluated the ability of all recombinant factor Va molecules
to function as a cofactor for prothrombinase. A clotting assay
using factor V-deﬁcient plasma and an R-thrombin generation
assay using Spectrozyme-TH and puriﬁed reagents were
employed. In addition, we have followed the activation of
prothrombin by gel electrophoresis. Figure 3B illustrates the
ﬁtted hyperbolic plots used to extract the kinetic constants
obtained following plasma-derived prothrombin activation
by prothrombinase assembled with all control or modiﬁed
cofactor molecules, and summarized in Table 1. Because we
wanted to prevent the possibility that differences between
prothrombinase assembled with factor VaWt and prothrom-
binase assembled with factor Va∆680-709 or factor Va4A may
be attributed to subtle differences in the KDapp of factor Va
for factor Xa, which would result in a smaller amount of
prothrombinase formed, all experiments described below
were conducted under conditions in which more than 95%
of factor Xa was saturated with factor Va. The amount of
factor Xa saturation by each cofactor was calculated using
the quadratic equation provided in the literature (50) and the
KDapp obtained from the data shown in Figure 3A. The percent
saturation of factor Xa by each cofactor species and the
correlation coefﬁcient (R2) of the ﬁtted hyperbolic plots used
to extract the values of Vmax and Km are provided in the
legend of Figure 3B together with the actual reagent
concentrations used in each experiment.
Factor VaRVV
∆680-709 had a 39.2% greater kcat [Figure 3B
(O)] and 73% lower clotting activity than factor VaRVV
Wt
[Figure 3B (3)], while factor VaIIa/CG had a 23.7% greater
kcat and 62% lower clotting activity than factor VaIIa
PLASMA
(Table 1). In separate experiments, we have found that under
similar experimental conditions, factor VaIIa/NN that has a 50%
lower clotting activity than the plasma cofactor (21) had a
20.5% increased kcat compared to that of factor VaIIa
PLASMA
(Table 1). All these data are in complete agreement with
earlier and recent ﬁndings (18–21, 37) and demonstrate that
elimination of the COOH-terminal region of the factor Va
heavy chain produces a molecule with poor clotting activity,
yet when the truncated cofactor is incorporated into pro-
thrombinase, it produces an enzyme with increased catalytic
efﬁciency for prothrombin activation as assessed using
FIGURE 2: Electrophoretic analyses of wild-type factor V and
recombinant factor V molecules. (A) Factor VWt and factor V∆680-709
were activated with RVV-V activator. (B) Factor VWt and factor
V4A were activated with R-thrombin as described in Experimental
Procedures and analyzed by SDS-PAGE. After being transferred
to a PVDF membrane, immunoreactive fragments were detected
with monoclonal antibodies RHFVaHC17 (recognizing an epitope
on the heavy chain of the cofactor between amino acid residues
307 and 506) and RHFVaHC9 (recognizing the light chain). At the
right, the positions of the heavy and light chains of factor Va are
shown.
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majority of membrane-bound cofactor is bound to factor Xa.
Overall, the data listed in Table 1 also demonstrate that the
plasma and wild-type molecule behave similarly following
activation by either RVV-V activator or R-thrombin with
respect to prothrombin activation. These data are in complete
accord with earlier ﬁndings (20, 21) and demonstrate that
plasma and wild-type factor Va are interchangeable. As a
consequence, throughout this work control experiments were
conducted, and their results are shown with only one of the
two molecules as indicated.
We next evaluated the ability of prothrombinase assembled
with the truncated molecules to activate prothrombin by gel
electrophoresis. Under the conditions that were employed,
prothrombinase assembled with factor VaRVV
Wt activates
prothrombin quickly, with meizothrombin as a short-lived
intermediate as demonstrated by the brief half-life of
fragment 1·2-A (Figure 4A). Scanning densitometry dem-
onstrated a peak of meizothrombin early in the reaction at
80 s, and no meizothrombin was detected following 180 s
(Figure 5A). In contrast, in the presence of prothrombinase
assembled with factor Va∆680-709, prothrombin is consumed
with a rate that is approximately 3-fold slower than the rate
of consumption of prothrombin by prothrombinase assembled
with the wild-type molecule (Table 1), with persistence of
meizothrombin as indicated by the lingering of fragment
1·2-A even at the late time points of the reaction (Figure
4B). Scanning densitometry demonstrated a peak of meizo-
thrombin late in the reaction at 250 s. Meizothrombin was
more concentrated and persisted for up to 6 min (Figure 5B).
In addition, the rate of appearance of the B chain is also
delayed (by approximately 3-fold) when prothrombin is
activated by prothrombinase assembled with factor
Va∆680-709, compared with the rate of appearance of the B
chain obtained following incubation of prothrombin with
prothrombinase assembled with factor VaRVV
Wt. Similar
results were obtained with factor VaIIa/CG (Table 1). In
contrast, in the presence of DYDYQ, no meizothrombin is
observed following prothrombin activation by prothrombi-
nase assembled with factor Va∆680-709, and R-thrombin is
formed through the alternate pathway characterized by initial
cleavage at Arg271 and formation of prethrombin 2 as the
intermediate (Figure 4C). Overall, the data demonstrate that
elimination of amino acid region 680-709 from factor Va
results in a cofactor molecule that when incorporated into
prothrombinase produces an enzyme responsible for both
delayed prothrombin activation and persistence of meizo-
thrombin during activation of prothrombin.
In preliminary experiments using several preparations
of recombinant proteins, we observed that while the
truncated factor Va molecules are impaired in their clotting
activity, factor Va4A is also deﬁcient in its clotting activity.
To understand the properties of this molecule and the
effect of the mutations on cofactor activity, we used the
same preparation of recombinant protein to perform three
different experiments. Factor V4A was ﬁrst activated with
R-thrombin, and the solution was split into three separate
samples. One sample was used for assessment of clotting
activity, one sample was used to measure the kinetic
parameters of prothrombinase assembled with a saturating
concentration of factor VaIIa
4A, and the third sample was
used for analysis of prothrombin activation by gel elec-
FIGURE 3: Raw data used for the determination of the parameters of
prothrombinase complex assembly and function. (A) Determination
of the afﬁnity of recombinant factor Va molecules for plasma-derived
factor Xa. Initial rates of R-thrombin generation were determined as
described in Experimental Procedures. Data for prothrombinase
assembled with factor VaWt are shown with ﬁlled squares (R2 )0.979),
while data for prothrombinase assembled with FVa∆680-709 are depicted
with ﬁlled triangles (R2 ) 0.978). Titrations were carried out to 20
nM factor Va; however, for graphical purposes, the data show the
titration up to 10 nM cofactor. The solid lines represent a nonlinear
regression ﬁt of the data as detailed in Experimental Procedures using
Prizm and the model for one binding site. The apparent dissociation
constant (KDapp) for each species was obtained from each titration
performed at least in triplicate with at least two different prepara-
tions of recombinant proteins and is listed in the inset. (B)
Determination of kinetic parameters of prothrombinase assembled
with various factor Va species. Initial rates of R-thrombin generation
were determined using the KD for factor Xa found in panel A to
determine the concentration of factor Va as described in Experi-
mental Procedures in the presence of PCPS vesicles and factor Xa.
Data for prothrombinase assembled with two different concentra-
tions of factor VaWt
RVV are shown with empty triangles (10 nM,
95% factor Xa saturation; R2 ) 0.97) and empty inverted triangles
(20 nM, 97% factor Xa saturation; R2 ) 0.97). Data for prothrom-
binase assembled with two different concentrations of factor
Va∆680-709 are depicted with ﬁlled diamonds (10 nM, 96% factor
Xa saturation; R2 ) 0.98) and empty circles (20 nM, 98% factor
Xa saturation; R2 ) 0.99), while data for prothrombinase assembled
with factor VaIIa
PLASMA are depicted with ﬁlled squares (10 nM,
98% factor Xa saturation; R2 ) 0.97) and with factor VaRVV
PLASMA
with empty diamonds (10 nM, 98% factor Xa saturation; R2 ) 0.97).
Data for prothrombinase assembled with factor VaRVV
4A are depicted
with ﬁlled inverted triangles (10 nM, 96.5% factor Xa saturation;
R2 ) 0.98). The values of Km and Vmax/ET () kcat) extracted directly
from these graphs are listed in Table 1.
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4A is
severely impaired in its clotting activity (∼22% of that
of factor VaIIa
Wt), prothrombinase assembled with the
mutant molecule shows a 19.7% increased kcat (Table 1).
Gel electrophoresis followed by scanning densitometry
analysis demonstrated that prothrombinase assembled with
factor VaIIa
4A cleaves prothrombin with a rate that is
approximately 3.8-fold slower than the rate of cleavage
of prothrombin assembled with factor VaIIa
Wt or factor
VaIIa
PLASMA (Figure 4D,E and Table 1). Scanning densi-
tometry of several gels studying prothrombin activation
by prothrombinase assembled with factor VaIIa
4A revealed
a peak of meizothrombin at approximately 240 s with
signiﬁcant amounts of meizothrombin remaining for up
to 10 min (not shown). The data also showed more
meizothrombin formed and delayed B chain formation by
prothrombinase assembled with factor Va4A as compared
to the levels of meizothrombin produced by prothrombi-
Table 1: Characteristics of Various Factor Va Molecules Assembled into Prothrombinase
a
FVaIIa
PLASMA FVaRVV
PLASMA FVaIIa
Wt FVaRVV
Wt FVaRVV
∆680-709 FVaIIa/CG
d FVaIIa/NN FVaIIa
4A FVaRVV
4A
II Consumption
b
[mol s-1 (mol of fXa)-1]
16.2 ( 1.8 ND
f 17.3 ( 1.2 15.8 ( 1.1 5.1 ( 0.54 5.9 ( 0.6 ND
f 4.4 ( 0.42 4.7 ( 0.4
Km (µM) 0.1 ( 0.011 0.24 ( 0.04 0.1 ( 0.013 0.22 ( 0.04 0.24 ( 0.03 0.26 ( 0.03 0.15 ( 0.07 0.31 ( 0.1 0.25 ( 0.03
kcat (min-1) 1715 ( 45 1754 ( 84 1697 ( 48 1721 ( 90 2396 ( 71 2122 ( 62 2066 ( 86 2031 ( 81 2018 ( 75
speciﬁc activity (units/mg)
c 3337 ( 480 2753 ( 267 2926 ( 340 3200 ( 550 869 ( 192 1280 ( 114 ND
e,f 663 ( 210 640 ( 120
a The rate of thrombin formation following activation of prothrombin by prothrombinase assembled with the various factor Va species was calculated
as described in Experimental Procedures with the knowledge of the dissociation constant of each factor Va species for factor Xa. In each case, more
than 95% of factor Xa was saturated with factor Va. Some of the data in the table were extracted directly from the graphs shown in Figure 3B.
b The
rate of prothrombin consumption was determined following quantitative scanning densitometry of several gels stained with Coomassie Blue as described
in Experimental Procedures. Some of the gels used are shown in Figure 4.
c All clotting activities were determined in a two-stage clotting assay
following activation of factor V species by RVV-V activator or R-thrombin as described previously (39, 40).
d Plasma factor V was activated with
R-thrombin and treated with cathepsin G (CG) as described previously (20).
e The clotting activity of the truncated cofactor is ∼50% of that of
plasma-derived factor Va (21).
f Not determined in this study.
FIGURE 4: Analysis of the activation of plasma-derived prothrombin by prothrombinase. Plasma-derived prothrombin (1.4 µM) was incubated
in different mixtures with PCPS vesicles (20 µM), and prothrombinase assembled with either wild-type factor Va [(A) 10 nM] or factor
Va∆680-709 [(B) 10 nM] as described in Experimental Procedures, and the reaction was started by the addition of factor Xa. (C) Prothrombinase
assembled with factor Va∆680-709 in the presence of 20 µM DYDYQ (same conditions as in panel B). (D) Prothrombinase assembled with
plasma-derived factor Va (10 nM). (E) Prothrombinase assembled with factor Va4A (10 nM). At selected time intervals, aliquots of the
reaction mixtures were withdrawn and treated as described in Experimental Procedures. Lane M contained the molecular weight markers
(from top to bottom): 98000, 64000, 50000, 36000, and 22000. Lanes 1-19 represent samples from the reaction mixture before (0 min) the
addition of factor Xa and 20 s, 40 s, 60 s, 80 s, 100 s, 120 s, 140 s, 160 s, 180 s, 200 s, 220 s, 240 s, 5 min, 6 min, 10 min, 20 min, 30
min, and 60 min, respectively, following the addition of factor Xa. The prothrombin-derived fragments are shown as follows: II, prothrombin
(amino acid residues 1-579); prethrombin-1 (amino acid residues 156-579); F1·2-A, fragment 1·2-A chain (amino acid residues 1-320);
F1·2, fragment 1·2 (amino acid residues 1-271); P2, prethrombin-2 (amino acid residues 272-579); P2′, prethrombin-2 cleaved at Arg284;
B, B chain of R-thrombin (amino acid residues 321-579).
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obtained with factor VaRVV
4A (Table 1). These ﬁndings
strongly support our previous conclusion suggesting that
amino acid sequence 695-699 regulates meizothrombin
formation by prothrombinase (35, 36). These data also
demonstrate that, in the presence of prothrombinase
assembled with factor Va4A, the excess meizothrombin
formed as assessed functionally by clotting assays can
compensate for the absence of R-thrombin in the assay
using puriﬁed reagents because the increased amidolytic
activity of meizothrombin toward the chromogenic sub-
strate is read as R-thrombin activity.
Role of the Acidic COOH-Terminal Portion of the Factor
Va HeaVy Chain: A Potential Mechanism. The data obtained
thus far studying plasma-derived prothrombin activation by
prothrombinase assembled with the mutant cofactor mol-
ecules suggest that meizothrombin formation is not greatly
delayed but rather that meizothrombin accumulates to higher
and more persistent levels and lingers throughout the time
course (Figure 5B). The appearance of the B chain of
R-thrombin is also delayed when prothrombin is activated
by prothrombinase assembled with the mutant cofactor
(Figures 4 and 5). These data indicate that one or both of
the two prothrombin activation cleavages are impaired
(affected) when prothrombinase is assembled with a cofactor
molecule missing the acidic COOH terminus of the heavy
chain or with factor Va4A. To verify if under the conditions
employed, cleavage at Arg320 in prothrombin is delayed when
prothrombinase is assembled with factor VaIIa
4A as compared
to cleavage of prothrombin at the same site by prothrombi-
nase assembled with factor VaIIa
Wt, we studied prothrombin
cleavage during the ﬁrst 90 s of the reaction. Quantitative
scanning densitometry of the gels revealed no differences
in the rate of plasma-derived prothrombin consumption by
prothrombinase assembled with either factor VaIIa
4A or factor
VaWt during this period of time (not shown). These data
combined with the data shown in Figures 4 and 5 illustrating
delayed prothrombin consumption which is accompanied by
an increase in the concentration of meizothrombin (up to
∼20%) in the case of the activation of prothrombin by
prothrombinase assembled with factor Va∆680-709 as com-
pared to the concentration of meizothrombin produced
following activation of prothrombin by prothrombinase
assembled with factor VaWt suggest that delayed initial
cleavage at Arg320 in plasma-derived prothrombin is not a
direct consequence of the mutation in factor Va, but rather
the result of product inhibition by the accumulating meizo-
thrombin. This inhibition is observed only late in the reaction
when sufﬁcient meizothrombin accumulates, as clearly
demonstrated by our combined results.
It is important to note that during the course of the assay
using plasma-derived prothrombin we are measuring the sum
of meizothrombin and R-thrombin. A more rigorous test to
verify which cleavage in prothrombin is affected by the
deletion at the COOH terminus of factor Va heavy chain
involves the study of the activation of a prothrombin
molecule that cannot be cleaved at Arg271 such as rMZ-II
(41). In addition, while cleavage of rMZ-II can be followed
by gel electrophoresis, generation of rMZ-IIa can be also
assessed with the chromogenic substrate used to assess
R-thrombin formation. We thus followed activation of rMZ-
II by prothrombinase assembled with either factor
VaRVV
∆680-709 or factor VaRVV
Wt by gel electrophoresis
(Figure 6A) and activity assays using Spectrozyme-TH
(Figure 6B). Both sets of data demonstrate that there are no
signiﬁcant differences between the rates of activation of rMZ-
II by either enzyme. The rates of rMZ-II consumption were
similar as determined by scanning densitometry of the gels
depicted in Figure 6A, and the proﬁles of both titrations are
coincident [similar Vmax values and similar Km values of 91
( 9 and 121 ( 18 µM (Figure 6B)]. Comparable results
FIGURE 5: Reaction proﬁles for the activation of prothrombin by
prothrombinase. Progress curves for products and reactants for the
activation of prothrombin by prothrombinase assembled with factor
VaWt (A) or factor Va∆680-709 (B) were obtained by quantitative
scanning densitometry of gels shown in panels A and B of Figure
4, as described in Experimental Procedures. The graphs illustrate
the disappearance of prothrombin (9), the transient formation of
meizothrombin (O), and the accumulation of the B chain of
R-thrombin (b). There is a 3-fold difference in the x-axis between
the two panels, because prothrombinase assembled with factor
Va∆680-709 consumes prothrombin with an ∼3-fold slower rate than
prothrombinase assembled with factor VaWt. The lines for the
disappearance of prothrombin were drawn according to the equation
of a one-phase exponential decay (for factor VaWt, R2 ) 0.985;
and for factor Va∆680-709, R2 ) 0.968). The lines depicting the
formation of meizothrombin and the accumulation of the B chain
of R-thrombin were arbitrarily drawn. Additional data points
extending to incubation for 1 h (shown in Figure 4) have been
omitted for clarity.
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different preparations of recombinant factor Va molecules
and two separate preparations of rMZ-II. The data conﬁrm
our overall ﬁndings with plasma-derived prothrombin and
demonstrate that prothrombinase-mediated cleavage at Arg320
in prothrombin is not affected by the COOH-terminal portion
of the factor Va heavy chain.
Analysis of the results obtained thus far suggests that
cleavage of meizothrombin at Arg271 by prothrombinase
assembled with factor VaRVV
∆680-709 may be slower than
cleavage of meizothrombin at the same site by prothrombi-
nase assembled with factor VaRVV
Wt, resulting in slower
conversion of meizothrombin to R-thrombin. We next
compared the rate of cleavage of FPR-meizothrombin by
prothrombinase assembled with various factor Va molecules
(Figure 7). The data demonstrate a delay for cleavage of
FPR-meizothrombin at Arg271 by prothrombinase assembled
with factor VaRVV
∆680-709 (panel C) or factor VaRVV
4A (panel
D) as compared to the same reaction catalyzed by prothrom-
binase assembled with factor VaRVV
PLASMA (panel B) or factor
VaRVV
Wt (not shown). A direct comparison between the rates
of cleavage of FPR-meizothrombin by membrane-bound
factor Xa alone (Figure 7A) or by prothrombinase assembled
with either factor VaRVV
∆680-709 (Figure 7C) or factor VaRVV
4A
(Figure 7D) does not show any signiﬁcant differences. These
data imply that following incorporation of factor Va into
prothrombinase it is the acidic COOH-terminal hirudin-like
portion of the factor Va heavy chain and in particular amino
acid sequence 695DYDY698 that is responsible for the increase
in the rate of cleavage of meizothrombin at Arg271. Quantita-
tive scanning densitometry of fragment 1·2-A present on
the gels shown in Figure 7 demonstrated an ∼3-5-fold delay
in cleavage of FPR-meizothrombin at Arg271 by either
membrane-bound factor Xa alone or prothrombinase as-
sembled with the recombinant mutant factor Va molecules,
compared to cleavage at Arg271 by prothrombinase assembled
with the plasma-derived cofactor (Figure 7B) or factor VaWt.
These data are in complete agreement with all the ﬁndings
presented herein and demonstrate that the lingering of
meizothrombin during plasma-derived prothrombin activation
by prothrombinase assembled with factor VaRVV
∆680-709 or
factor Va4A is the result of impaired cleavage of the molecule
at Arg271. Overall, the ﬁndings suggest that amino acid
sequence 695DYDY698 from the COOH-terminal portion of
the factor Va heavy chain regulates meizothrombin concen-
tration (processing) during activation of prothrombin by
prothrombinase.
DISCUSSION
Our data demonstrate that the acidic COOH terminus of
the factor Va heavy chain is responsible for coordinate
activation of prothrombin, resulting in timely R-thrombin
formation at the place of vascular injury. Furthermore, our
ﬁndings appear to resolve many apparently conﬂicting results
and explain the observation that was initially reported 15
years ago (18) and veriﬁed several times with either truncated
plasma-derived factor Va (19–21) or more recently with
recombinant factor Va molecules (37). Namely, incorporation
of cofactor molecules with a truncated heavy chain into
prothrombinase results in the enhanced stability of meizo-
thrombin during prothrombin activation. Our ﬁndings assign
an important physiological role to the COOH terminus of
the factor Va heavy chain for efﬁcient prothrombin activation
and conﬁrm the fact that the sequence 695DYDY698 regulates
the activity of factor Xa within prothrombinase (36).
We show that while rMZ-II is cleaved with equivalent rates
by either prothrombinase assembled with factor VaWt or
prothrombinase made with factor Va∆680-709, acceleration of
the rate of FPR-meizothrombin cleavage at Arg271 by
prothrombinase assembled with factor Va4A or factor
Va∆680-709 is impaired, compared to the rate of cleavage at
the same bond by prothrombinase assembled with factor
VaPLASMA or factor VaWt. Altogether, these ﬁndings demon-
FIGURE 6: Analysis of the activation of rMZ-II. (A) Gel electro-
phoretic analyses. rMZ-II (1.4 µM) was incubated in different
mixtures with PCPS vesicles (20 µM), DAPA (3 µM), and factor
VaWt (left panel, 20 nM) or factor Va∆680-709 (right panel, 20 nM).
The reaction was started by the addition of factor Xa, and the
samples were treated as detailed in Experimental Procedures. Lanes
1-9 contained samples of the reaction mixture following incubation
of prothrombinase with rMZ-II before (lane 1) or following
incubation for 0.5, 1, 2.5, 4, 6, 10, 20, and 30 min with factor Xa,
respectively. Positions of prothrombin-derived fragments are indi-
cated at the right as detailed in the legend of Figure 4. The factor
Va species used for the reconstitution of prothrombinase are shown
under each panel. (B) Kinetic analyses. Initial rates of R-thrombin
generation were determined as described in Experimental Proce-
dures, and the data were plotted according to the Michaelis-Menten
equation. Data for activation of rMZ-II by prothrombinase as-
sembled with factor VaWt are shown with ﬁlled squares (R2 ) 0.98),
while data for activation of rMZ-II by prothrombinase assembled
with factor Va∆680-709 are depicted with ﬁlled triangles (R2 ) 0.96).
Kinetic constants reported in the text were extracted directly from
the graphs.
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(i.e., Arg320) is not signiﬁcantly affected by the deletion of
the COOH-terminal portion of the factor Va heavy chain,
the rate of cleavage of meizothrombin at Arg271 by pro-
thrombinase appears to be regulated by the acidic hirudin-
like COOH-terminal portion of the heavy chain. Our data
show that prothrombinase assembled with factor VaPLASMA
or factor VaWt cleaves FPR-meizothrombin with a rate that
is 4-5-fold higher than the rate of cleavage of FPR-
meizothrombin by factor Xa alone or by prothrombinase
assembled with the mutant molecules. These ﬁndings are in
complete accord with earlier data demonstrating that incor-
poration of factor Va into prothrombinase results in a 3-5-
fold increase in the rate of cleavage of meizothrombin at
Arg271 as compared to the rate of cleavage at the same site
by factor Xa alone (7, 8).
Recently, we have demonstrated that formation of meizo-
thrombin by prothrombinase assembled with the plasma-
derived cofactor is inhibited in the presence of low concen-
trations of an acidic region from the carboxyl-terminal
portion of factor Va (represented by pentapeptide DYDYQ)
(36). The combined ﬁndings demonstrate that amino acid
sequence 695-698 is responsible for the regulation of
meizothrombin processing and suggest that peptide DYDYQ
inhibits meizothrombin generation by prothrombinase by
accelerating the rate of cleavage at Arg271 by the enzyme,
thus practically alleviating the factor Va cofactor effect within
prothrombinase. As a result, in the presence of DYDYQ,
cleavage of prothrombin by prothrombinase becomes virtu-
ally independent of factor Va. These ﬁndings are in complete
accord with our recent data demonstrating that DYDYQ
signiﬁcantly increases the rate of cleavage of prothrombin
consumption by membrane-bound factor Xa alone because
of acceleration of the cleavage at Arg271 (36). Indeed,
membrane-bound factor Xa/DYDYQ, in the absence of factor
Va, cleaves prothrombin with a rate that is ∼5-fold slower
than the rate of cleavage of prothrombin by prothrombinase
(ref 36 and Table 1), while membrane-bound factor Xa alone
cleaves prothrombin with a rate that is ∼250-fold slower
than the rate of cleavage of the substrate by prothrombinase.
However, it is noteworthy that in the presence of an excess
of DYDYQ, prothrombin cleavage by prothrombinase is
signiﬁcantly inhibited (36). Altogether, these ﬁndings warrant
the need for further investigation of the mode of action and
site of interaction with prothrombin of the pentapeptide as
well as of the molecular mechanism of inhibition of
prothrombinase by DYDYQ.
Blood clotting enzymes, with the exception of factor IX
and prothrombin, are activated following single proteolytic
cleavage (1). It is thus assumed that results obtained
following the activation of a zymogen either by gel elec-
trophoresis or by assays that measure the generation of
FIGURE 7: Gel electrophoretic analyses for cleavage of FPR-meizothrombin. FPR-meizothrombin (1.4 µM) was incubated in different mixtures
with PCPS vesicles (20 µM) and factor Va as described in the legend of Figure 4. The reaction and the samples were further treated,
scanned, and quantiﬁed as detailed in Experimental Procedures: (A) control, no factor Va [13.4 mol of FPR-meizo consumed s-1 (mol of
factor Xa)-1], (B) factor VaRVV
PLASMA [42.6 mol of FPR-meizo consumed s-1 (mol of factor Xa)-1], (C) factor VaRVV
∆680-709 [8.4 mol of
FPR-meizo consumed s-1 (mol of factor Xa)-1], and (D) factor VaRVV
4A [14.6 mol of FPR-meizo consumed s-1 (mol of factor Xa)-1]. Lane
M contained the molecular weight markers (from top to bottom): 50000, 36000, and 22000. Lanes 1-19 contained samples from the
reaction mixture before (0 min) the addition of factor Xa and 20 s, 40 s, 60 s, 80 s, 100 s, 120 s, 140 s, 160 s, 180 s, 200 s, 220 s, 240 s,
5 min, 6 min, 10 min, 20 min, 30 min, and 60 min, respectively, following the addition of factor Xa. The prothrombin-derived fragments
are shown as detailed in the legend of Figure 4. The factor Va species used for the reconstitution of prothrombinase are also shown under
each panel.
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concordant. However, prothrombin activation is different
from the activation of other zymogens because (1) prothrom-
bin can be activated through two different pathways that have
different requirements and signiﬁcantly different rates and
(2) activation of prothrombin through the meizothrombin
pathway generates an intermediate that has higher amidolytic
activity than R-thrombin toward chromogenic substrates that
are commonly used to assess R-thrombin generation. Thus,
while following prothrombin activation by both gel electro-
phoresis and activity assays simultaneously may appear to
be a duplication of the same result, drawing conclusions from
activity assays alone without analyzing the pathway to
prothrombin activation and the intermediates formed is an
oversimpliﬁcation that can lead to erroneous conclusions.
Two assays are used worldwide for the determination of
factor Va cofactor activity: a clotting assay using factor
V-deﬁcient plasma and a prothrombinase assay using puriﬁed
reagents. The former assay is performed at low (limiting)
concentrations of factor Va, while the latter assay is conducted
with high (saturating) concentrations of factor Va with respect
to factor Xa. Both assays indirectly report on factor Va cofactor
activity through the activation of prothrombin to R-thrombin.
The clotting time measures the level of ﬁbrin formation in factor
V-deﬁcient plasma, while the prothrombinase assay measures
R-thrombin’s amidolytic activity as it is generated toward a
chromogenic substrate. Initial cleavage of prothrombin at Arg320
by prothrombinase, which is absolutely factor Va-dependent,
results in rapid meizothrombin generation. However, depending
on the ratio of meizothrombin to R-thrombin formed at the
moment the measurement is taken, the results reﬂect the clotting
or amidolytic activity of either R-thrombin or meizothrombin
or the sum of both. Thus, if generation of R-thrombin is delayed
compared to the formation of meizothrombin, the measurements
will mostly reﬂect the properties of meizothrombin (i.e.,
impaired clotting and increased chromogenic activity).
Work performed independently in several laboratories
worldwide has demonstrated that while elimination of the
COOH-terminal acidic region of factor Va heavy chain
results in a cofactor molecule with poor clotting activity
(retaining 20-40% of the clotting activity of normal factor
Va), the same molecule as part of prothrombinase produces
a substantial increase in the kcat of the enzyme in an assay
using a chromogenic substrate to assess R-thrombin genera-
tion (18–21) (Table 2). Similar results were recently obtained
with recombinant factor Va molecules missing portions of
the COOH terminus of the factor Va heavy chain (37). All
these results could be partially explained if the truncated
cofactor molecules had weakened binding capabilities for
membrane-bound factor Xa. However, previously reported
data demonstrated that all truncated factor Va molecules have
KD values for factor Xa similar to that of the plasma-derived
cofactor (20, 21), and recent experiments with recombinant
factor Va molecules missing the entire hirudin-like COOH-
terminal portion of the factor Va heavy chain (amino acids
679-709, rFVa678) conﬁrm our ﬁndings shown in Figure 3A
with factor Va∆680-709 and demonstrate that the recombinant
mutant cofactor binds factor Xa with an afﬁnity similar to
that of the wild-type molecule (37). Thus, while every study
was remarkably consistent in showing poor clotting and
increased kcat for the same truncated factor Va molecules
[up to ∼50% higher kcat (37) (Table 2)], no satisfactory
explanation has been yet provided to explain this seeming
paradox at best (18–21), or at worst the observations were
simply discarded as relatively modest changes (37). Our data,
put in the context of the literature, provide a logical
explanation for these observations and demonstrate that the
acidic COOH-terminal portion of the factor Va heavy chain
controls the rate of R-thrombin generation by factor Xa
within prothrombinase by controlling the rate of meizo-
thrombin cleavage at Arg271. Our ﬁndings are thus consistent
with the interpretation that amino acid sequence 695DYDY698
of the heavy chain of the cofactor is a signiﬁcant contributor
to the macromolecular substrate recognition of prothrombin
by prothrombinase.
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